Literature DB >> 19713461

Acute graft-versus-host disease: from the bench to the bedside.

Gerard Socié1, Bruce R Blazar.   

Abstract

During the past decade, progress in basic immunology has been impressive. In parallel, whereas our understanding of the pathophysiology of acute graft-versus-host disease (GVHD) has greatly improved, so has our knowledge of the complexities of the immune system. Much of the immunobiology of acute GVHD has been gleaned from preclinical models and far less from correlations with clinical observations or therapeutic interventions. In this review, we summarize some of the major advances in GVHD pathophysiology, including the translation of these from the bench to the bedside, and discuss preclinical approaches that warrant further exploration in the clinic.

Entities:  

Mesh:

Year:  2009        PMID: 19713461      PMCID: PMC2777122          DOI: 10.1182/blood-2009-06-204669

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  130 in total

1.  Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation.

Authors:  Marco Mielcarek; Paul J Martin; Wendy Leisenring; Mary E D Flowers; David G Maloney; Brenda M Sandmaier; Michael B Maris; Rainer Storb
Journal:  Blood       Date:  2003-03-27       Impact factor: 22.113

2.  Relation of an interleukin-10 promoter polymorphism to graft-versus-host disease and survival after hematopoietic-cell transplantation.

Authors:  Ming-Tseh Lin; Barry Storer; Paul J Martin; Li-Hui Tseng; Ted Gooley; Pei-Jer Chen; John A Hansen
Journal:  N Engl J Med       Date:  2003-12-04       Impact factor: 91.245

3.  Minor histocompatibility antigen-specific cytotoxic T lymphocytes generated with dendritic cells from DLA-identical littermates.

Authors:  George E Georges; Marina Lesnikova; Rainer Storb; Murad Yunusov; Marie-Térèse Little; Richard A Nash
Journal:  Biol Blood Marrow Transplant       Date:  2003-04       Impact factor: 5.742

4.  LPAM (alpha 4 beta 7 integrin) is an important homing integrin on alloreactive T cells in the development of intestinal graft-versus-host disease.

Authors:  Aleksandra Petrovic; Onder Alpdogan; Lucy M Willis; Jeffrey M Eng; Andrew S Greenberg; Barry J Kappel; Chen Liu; George J Murphy; Glenn Heller; Marcel R M van den Brink
Journal:  Blood       Date:  2003-10-16       Impact factor: 22.113

5.  CC chemokine receptor 2 expression in donor cells serves an essential role in graft-versus-host-disease.

Authors:  Arun R Rao; Marlon P Quinones; Edgar Garavito; Yogeshwar Kalkonde; Fabio Jimenez; Caroline Gibbons; Jennifer Perez; Peter Melby; William Kuziel; Robert L Reddick; Sunil K Ahuja; Seema S Ahuja
Journal:  J Immunol       Date:  2003-11-01       Impact factor: 5.422

6.  Importance of minor histocompatibility antigen expression by nonhematopoietic tissues in a CD4+ T cell-mediated graft-versus-host disease model.

Authors:  Stephen C Jones; George F Murphy; Thea M Friedman; Robert Korngold
Journal:  J Clin Invest       Date:  2003-12       Impact factor: 14.808

7.  FTY720 does not abrogate acute graft-versus-host disease in the dog leukocyte antigen-nonidentical unrelated canine model.

Authors:  Richard S Lee; Christian S Kuhr; George E Sale; Eustacia Zellmer; William J Hogan; Rainer Storb; Marie-Térèse Little
Journal:  Transplantation       Date:  2003-10-27       Impact factor: 4.939

8.  Blockade of programmed death-1 engagement accelerates graft-versus-host disease lethality by an IFN-gamma-dependent mechanism.

Authors:  Bruce R Blazar; Beatriz M Carreno; Angela Panoskaltsis-Mortari; Laura Carter; Yoshiko Iwai; Hideo Yagita; Hiroyuki Nishimura; Patricia A Taylor
Journal:  J Immunol       Date:  2003-08-01       Impact factor: 5.422

9.  In vivo imaging of graft-versus-host-disease in mice.

Authors:  Angela Panoskaltsis-Mortari; Andrew Price; John R Hermanson; Elizabeth Taras; Chris Lees; Jonathan S Serody; Bruce R Blazar
Journal:  Blood       Date:  2004-01-08       Impact factor: 22.113

10.  CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation.

Authors:  Matthias Edinger; Petra Hoffmann; Joerg Ermann; Kathryn Drago; C Garrison Fathman; Samuel Strober; Robert S Negrin
Journal:  Nat Med       Date:  2003-08-17       Impact factor: 53.440

View more
  112 in total

1.  Induction of transplantation tolerance to fully mismatched cardiac allografts by T cell mediated delivery of alloantigen.

Authors:  Chaorui Tian; Xueli Yuan; Peter T Jindra; Jessamyn Bagley; Mohamed H Sayegh; John Iacomini
Journal:  Clin Immunol       Date:  2010-05-08       Impact factor: 3.969

2.  Alloantigen expression on non-hematopoietic cells reduces graft-versus-leukemia effects in mice.

Authors:  Shoji Asakura; Daigo Hashimoto; Shuichiro Takashima; Haruko Sugiyama; Yoshinobu Maeda; Koichi Akashi; Mitsune Tanimoto; Takanori Teshima
Journal:  J Clin Invest       Date:  2010-06-07       Impact factor: 14.808

3.  Blocking IL-21 signaling ameliorates xenogeneic GVHD induced by human lymphocytes.

Authors:  Keli L Hippen; Christoph Bucher; Dawn K Schirm; Amanda M Bearl; Ty Brender; Kathy A Mink; Kimberly S Waggie; Regis Peffault de Latour; Anne Janin; Julie M Curtsinger; Stacey R Dillon; Jeffrey S Miller; Gerard Socie; Bruce R Blazar
Journal:  Blood       Date:  2011-11-10       Impact factor: 22.113

4.  Regulation of acute graft-versus-host disease by microRNA-155.

Authors:  Parvathi Ranganathan; Catherine E A Heaphy; Stefan Costinean; Nicole Stauffer; Caroline Na; Mehdi Hamadani; Ramasamy Santhanam; Charlene Mao; Patricia A Taylor; Sukhinder Sandhu; Gang He; Arwa Shana'ah; Gerard J Nuovo; Alessandro Lagana; Luciano Cascione; Susanna Obad; Oliver Broom; Sakari Kauppinen; John C Byrd; Michael Caligiuri; Danilo Perrotti; Gregg A Hadley; Guido Marcucci; Steven M Devine; Bruce R Blazar; Carlo M Croce; Ramiro Garzon
Journal:  Blood       Date:  2012-03-09       Impact factor: 22.113

5.  TCR affinity and specificity requirements for human regulatory T-cell function.

Authors:  Gabriela Plesa; Lingjie Zheng; Andrew Medvec; Caleph B Wilson; Camila Robles-Oteiza; Nathaniel Liddy; Alan D Bennett; Jessie Gavarret; Annelise Vuidepot; Yangbing Zhao; Bruce R Blazar; Bent K Jakobsen; James L Riley
Journal:  Blood       Date:  2012-02-07       Impact factor: 22.113

6.  IDO in human gut graft-versus-host disease.

Authors:  Philippe Ratajczak; Anne Janin; Régis Peffault de Larour; Lisa Koch; Brigitte Roche; David Munn; Bruce R Blazar; Gérard Socié
Journal:  Biol Blood Marrow Transplant       Date:  2011-08-09       Impact factor: 5.742

7.  Attenuation of acute graft-versus-host disease in the absence of the transcription factor RORγt.

Authors:  LeShara M Fulton; Michael J Carlson; James M Coghill; Laura E Ott; Michelle L West; Angela Panoskaltsis-Mortari; Dan R Littman; Bruce R Blazar; Jonathan S Serody
Journal:  J Immunol       Date:  2012-07-09       Impact factor: 5.422

8.  Ceramide synthesis regulates T cell activity and GVHD development.

Authors:  M Hanief Sofi; Jessica Heinrichs; Mohammed Dany; Hung Nguyen; Min Dai; David Bastian; Steven Schutt; Yongxia Wu; Anusara Daenthanasanmak; Salih Gencer; Aleksandra Zivkovic; Zdzislaw Szulc; Holger Stark; Chen Liu; Ying-Jun Chang; Besim Ogretmen; Xue-Zhong Yu
Journal:  JCI Insight       Date:  2017-05-18

9.  Complement component C3 mediates Th1/Th17 polarization in human T-cell activation and cutaneous GVHD.

Authors:  Q Ma; D Li; R Carreño; R Patenia; K Y Tsai; M Xydes-Smith; A M Alousi; R E Champlin; G E Sale; V Afshar-Kharghan
Journal:  Bone Marrow Transplant       Date:  2014-04-28       Impact factor: 5.483

10.  Mechanistic Assessment of PD-1H Coinhibitory Receptor-Induced T Cell Tolerance to Allogeneic Antigens.

Authors:  Dallas B Flies; Tomoe Higuchi; Lieping Chen
Journal:  J Immunol       Date:  2015-04-27       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.